CRIXIVAN
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
CRIXIVAN by Merck & Co. is mechanism of action: hiv-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious hiv-1. Approved for hiv infection. First approved in 1996.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CRIXIVAN (indinavir) is an oral HIV-1 protease inhibitor approved in 1996 that binds to the viral protease active site, preventing cleavage of viral polyproteins and formation of infectious particles. It is used to treat HIV infection by suppressing viral replication. The drug represents a foundational antiretroviral class that transformed HIV management from a fatal diagnosis to a chronic manageable condition.
LOE Approaching
As an approaching LOE product with moderate competitive pressure (30), the brand team is likely in maintenance mode with reduced headcount and budget allocation.
Mechanism of Action
Mechanism of Action: HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents…
Indications (1)
Clinical Trials (1)
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
200 enrolled
HIV Infections
Career Relevance
Worked on CRIXIVAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.